Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1

被引：0

作者：

Hubner, R. ^{[1
]}

Cubillo, A. ^{[2
]}

Blanc, J-F. ^{[3
]}

Melisi, D. ^{[4
]}

von Hoff, D. D. ^{[5
,6
]}

Wang-Gillam, A. ^{[7
]}

Chen, L-T. ^{[8
]}

Becker, C. ^{[9
]}

Mamlouk, K. ^{[10
]}

Belanger, B. ^{[11
]}

Yang, Y. ^{[12
]}

de Jong, F. ^{[13
]}

Siveke, J. T. ^{[14
]}

机构：

[1] Christie Hosp NHS Fdn Trust, Med Oncol, Manchester, Lancs, England

[2] Ctr Integral Oncol Clara Campal, START Madrid, Madrid, Spain

[3] Hop St Andre, Oncol, Bordeaux, France

[4] Univ Verona, Digest Mol Oncol, Verona, Italy

[5] TGen & Honor Hlth, Med Oncol, Phoenix, AZ USA

[6] TGen & Honor Hlth, Med Oncol, Scottsdale, AZ USA

[7] Washington Univ, Div Oncol, St Louis, MO USA

[8] Natl Inst Canc Res, Natl Hlth Res Inst, Oncol, Tainan, Taiwan

[9] Merrimack Pharmaceut Inc, Market Access, Cambridge, MA USA

[10] Merrimack Pharmaceut Inc, Med Affairs, Cambridge, MA USA

[11] Merrimack Pharmaceut Inc, Biostat, Cambridge, MA USA

[12] Baxalta Inc, Oncol, Global HEOR, Cambridge, MA USA

[13] Baxalta GmbH, Shire, Oncol, Med Affairs, Zurich, Switzerland

[14] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

242P

引用

页数：1